GlaxoSmithKline Pharmaceuticals Limited — Updates, 06-11-2025: Press Release

GSK India's Q2FY26 revenue hit INR 974 Cr, with PAT at INR 255 Cr. EBIDTA margin grew 250 bps to 34.4%. Topline was muted due to temporary challenges and supply issues. New Oncology launches (Jemperli, Zejula) are performing strongly, complementing solid growth in vaccines and general medicines.